Top

Published in:

Open Access 01-12-2016 | Research

Generation of mAbs to foot–and–mouth disease virus serotype A and application in a competitive ELISA for serodiagnosis

Authors: Ming Yang, Wanhong Xu, Hilary Bittner, Jacquelyn Horsington, Wilna Vosloo, Melissa Goolia, Diana Lusansky, Charles Nfon

Published in: Virology Journal | Issue 1/2016

Abstract

Background

Foot–and–mouth disease (FMD) is an economically devastating disease that severely limits international trade of animals. Of the seven FMD virus (FMDV) serotypes, serotype A is one of the most widespread cross the world. Currently antibodies to FMDV are detected in animals using the virus neutralization test (VNT) and the enzyme-linked immunosorbent assay (ELISA). The VNT is laborious, time–consuming and reliant on live virus and cell cultures, while ELISA has the advantage of using inactivated antigens and often provides more reproducible results. The aim of this study was to develop a reliable and rapid competitive ELISA (cELISA) for the detection of antibodies to FMDV serotype A (FMDV/A).

Results

A panel of FMDV/A specific monoclonal antibodies (mAbs) was generated and their ability to compete with a polyclonal serum from FMDV/A–infected cattle was examined. Two mAbs inhibited the binding of a polyclonal serum to FMDV/A viruses. The binding epitopes of each were determined as conformational and located on the VP2 viral capsid protein. The FMDV/A cELISA was developed using these two mAbs and FMDV/A inactivated virus as antigen. The diagnostic specificity and sensitivity were 99.7 and 99.3% (98.5–100%) respectively, based on a predetermined cut–off of 50% inhibition. When analysing sera from animals experimentally infected with FMDV/A, the cELISA detected antibodies from 5-days post infection (dpi) and remained positive for at least 21–28 days post infection. Comparison based on the Kappa coefficient showed strong agreement (90–94%) between cELISA and VNT.

Conclusion

The cELISA results are comparable to the VNT for antibody detection making it a simple and reliable test to detect antibodies against FMDV/A.

Available only for authorised users

Grubman MJ, Baxt B. Foot-and-mouth disease. Clin Microbiol Rev. 2004;17(2):465–93.CrossRefPubMedPubMedCentral

King D, Henstock M. OIE/FAO FMD laboratory network annual report. Pirbright: IAH; 2015.

Upadhyaya S, Ayelet G, Paul G, King DP, Paton DJ, Mahapatra M. Genetic basis of antigenic variation in foot-and-mouth disease serotype A viruses from the Middle East. Vaccine. 2014;32(5):631–8.CrossRefPubMedPubMedCentral

Bari FD, Parida S, Tekleghiorghis T, Dekker A, Sangula A, Reeve R, Haydon DT, Paton DJ, Mahapatra M. Genetic and antigenic characterisation of serotype A FMD viruses from East Africa to select new vaccine strains. Vaccine. 2014;32(44):5794–800.CrossRefPubMedPubMedCentral

Knowles N, Nazem Shirazi M, Wadsworth J, Swabey K, Stirling J, Statham R, Li Y, Hutchings G, Ferris N, Parlak Ü. Recent spread of a new strain (A‐Iran‐05) of foot‐and‐mouth disease virus type A in the Middle East. Transbound Emerg Dis. 2009;56(5):157–69.CrossRefPubMed

Mohapatra JK, Subramaniam S, Pandey LK, Pawar SS, De A, Das B, Sanyal A, Pattnaik B. Phylogenetic structure of serotype A foot-and-mouth disease virus: global diversity and the Indian perspective. J Gen Virol. 2011;92(Pt 4):873–9.CrossRefPubMed

World Organisation for Animal Health. In: Office International des épizooties, editor. Manual of diagnostic tests and vaccines for terrestrial animals (mammals, birds and bees) [electronic resource]. Paris: Office International des épizooties; 2008 [Anonymous].

Yang M, Clavijo A, Li M, Hole K, Holland H, Wang H, Deng MY. Identification of a major antibody binding epitope in the non-structural protein 3D of foot-and-mouth disease virus in cattle and the development of a monoclonal antibody with diagnostic applications. J Immunol Methods. 2007;321(1–2):174–81.CrossRefPubMed

Sørensen K, De Stricker K, Dyrting K, Grazioli S, Haas B. Differentiation of foot-and-mouth disease virus infected animals from vaccinated animals using a blocking ELISA based on baculovirus expressed FMDV 3ABC antigen and a 3ABC monoclonal antibody. Arch Virol. 2005;150(4):805–14.CrossRefPubMed

10.

Yang M, Parida S, Salo T, Hole K, Velazquez-Salinas L, Clavijo A. Development of a competitive enzyme-linked immunosorbent assay for detection of antibodies against the 3B protein of foot-and-mouth disease virus. Clin Vaccine Immunol. 2015;22(4):389–97.CrossRefPubMedPubMedCentral

11.

Clavijo A, Wright P, Kitching P. Developments in diagnostic techniques for differentiating infection from vaccination in foot-and-mouth disease. Vet J. 2004;167(1):9–22.CrossRefPubMed

12.

Bronsvoort BM, Parida S, Handel I, McFarland S, Fleming L, Hamblin P, Kock R. Serological survey for foot-and-mouth disease virus in wildlife in eastern Africa and estimation of test parameters of a nonstructural protein enzyme-linked immunosorbent assay for buffalo. Clin Vaccine Immunol. 2008;15(6):1003–11.CrossRefPubMedPubMedCentral

13.

Mohapatra JK, Pandey LK, Sanyal A, Pattnaik B. Recombinant non-structural polyprotein 3AB-based serodiagnostic strategy for FMD surveillance in bovines irrespective of vaccination. J Virol Methods. 2011;177(2):184–92.CrossRefPubMed

14.

Ko YJ, Lee HS, Jeoung HY, Heo EJ, Ko HR, Chang BS, Joo HD, Gerelmaa U, Dashzeveg B, Tserendorj S, Sodnomdarjaa R, Park JH, Kweon CH, Cho IS, Paik SG. Use of a baculovirus-expressed structural protein for the detection of antibodies to foot-and-mouth disease virus type A by a blocking enzyme-linked immunosorbent assay. Clin Vaccine Immunol. 2010;17(1):194–8.CrossRefPubMed

15.

Yang M, Clavijo A, Suarez-Banmann R, Avalo R. Production and characterization of two serotype independent monoclonal antibodies against foot-and-mouth disease virus. Vet Immunol Immunopathol. 2007;115(1–2):126–34.CrossRefPubMed

16.

Maree FF, Blignaut B, Esterhuysen JJ, de Beer TA, Theron J, O'Neill HG, Rieder E. Predicting antigenic sites on the foot-and-mouth disease virus capsid of the South African territories types using virus neutralization data. J Gen Virol. 2011;92(Pt 10):2297–309.CrossRefPubMed

17.

Saiz JC, Gonzalez MJ, Borca MV, Sobrino F, Moore DM. Identification of neutralizing antigenic sites on VP1 and VP2 of type A5 foot-and-mouth disease virus, defined by neutralization-resistant variants. J Virol. 1991;65(5):2518–24.PubMedPubMedCentral

18.

Jacobson RH. Validation of serological assays for diagnosis of infectious diseases. Rev Sci Tech. 1998;17(2):469–526.PubMed

19.

Horsington J, Zhang Z, Bittner H, Hole K, Singanallur NB, Alexandersen S, Vosloo W. Early protection in sheep against intratypic heterologous challenge with serotype O foot-and-mouth disease virus using high-potency, emergency vaccine. Vaccine. 2015;33(3):422–9.CrossRefPubMed

20.

Barnett PV, Ouldridge EJ, Rowlands DJ, Brown F, Parry NR. Neutralizing epitopes of type O foot-and-mouth disease virus. I. Identification and characterization of three functionally independent, conformational sites. J Gen Virol. 1989;70(Pt 6):1483–91.CrossRefPubMed

21.

Mateu MG, Hernandez J, Martinez MA, Feigelstock D, Lea S, Perez JJ, Giralt E, Stuart D, Palma EL, Domingo E. Antigenic heterogeneity of a foot-and-mouth disease virus serotype in the field is mediated by very limited sequence variation at several antigenic sites. J Virol. 1994;68(3):1407–17.PubMedPubMedCentral

22.

Bolwell C, Brown AL, Barnett PV, Campbell RO, Clarke BE, Parry NR, Ouldridge EJ, Brown F, Rowlands DJ. Host cell selection of antigenic variants of foot-and-mouth disease virus. J Gen Virol. 1989;70(Pt 1):45–57.CrossRefPubMed

23.

Acharya R, Fry E, Stuart D, Fox G, Rowlands D, Brown F. The three-dimensional structure of foot-and-mouth disease virus at 2.9 Å resolution. 1989.

24.

Strohmaier K, Franze R, Adam KH. Location and characterization of the antigenic portion of the FMDV immunizing protein. J Gen Virol. 1982;59(Pt 2):295–306.CrossRefPubMed

25.

Vratskikh O, Stiasny K, Zlatkovic J, Tsouchnikas G, Jarmer J, Karrer U, Roggendorf M, Roggendorf H, Allwinn R, Heinz FX. Dissection of antibody specificities induced by yellow fever vaccination. PLoS Pathog. 2013;9(6):e1003458.CrossRefPubMedPubMedCentral

26.

Chénard G, Miedema K, Moonen P, Schrijver RS, Dekker A. A solid-phase blocking ELISA for detection of type O foot-and-mouth disease virus antibodies suitable for mass serology. J Virol Methods. 2003;107(1):89–98.CrossRefPubMed

27.

Hedger R, Barnett I, Gradwell D, Travassos Dias P. Serological tests for foot-and-mouth disease in bovine serum samples. Problems of interpretation. Rev Sci Tech Off Int Epiz. 1982;1(2):387–93.CrossRef

28.

Wekesa SN, Sangula AK, Belsham GJ, Tjornehoj K, Muwanika VB, Gakuya F, Mijele D, Siegismund HR. Characterisation of recent foot-and-mouth disease viruses from African buffalo (Syncerus caffer) and cattle in Kenya is consistent with independent virus populations. BMC Vet Res. 2015;11(1):1.CrossRef

29.

Dinka SK, Swaney LM, Vicar JW. Selection of a stable clone of the MVPK-1 fetal porcine kidney cell for assays of foot-and-month disease virus. Can J Microbiol. 1977;23(3):295–9.CrossRefPubMed

30.

Yang M, Goolia M, Xu W, Bittner H, Clavijo A. Development of a quick and simple detection methodology for foot-and-mouth disease virus serotypes O, A and Asia 1 using a generic RapidAssay Device. Virol J. 2013;10:125-422X-10-125.

31.

Yang M, Xu W, Goolia M, Zhang Z. Characterization of monoclonal antibodies against foot-and-mouth disease virus serotype O and application in identification of antigenic variation in relation to vaccine strain selection. Virol J. 2014;11:136-422X-11-136.

32.

Martinez HM. An efficient method for finding repeats in molecular sequences. Nucleic Acids Res. 1983;11(13):4629–34.CrossRefPubMedPubMedCentral

33.

Lipman DJ, Pearson WR. Rapid and sensitive protein similarity searches. Science. 1985;227(4693):1435–41.CrossRefPubMed

34.

Logan D, Abu-Ghazaleh R, Blakemore W, Curry S, Jackson T, King A, Lea S, Lewis R, Newman J, Parry N. Structure of a major immunogenic site on foot-and-mouth disease virus. Nature. 1993;362(6420):566–8.CrossRefPubMed

35.

Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605–12.CrossRefPubMed

36.

Golding SM, Hedger RS, Talbot P. Radial immuno-diffusion and serum-neutralisation techniques for the assay of antibodies to swine vesicular disease. Res Vet Sci. 1976;20(2):142–7.PubMed

Title: Generation of mAbs to foot–and–mouth disease virus serotype A and application in a competitive ELISA for serodiagnosis
Authors: Ming Yang
Wanhong Xu
Hilary Bittner
Jacquelyn Horsington
Wilna Vosloo
Melissa Goolia
Diana Lusansky
Charles Nfon
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Virology Journal / Issue 1/2016
Electronic ISSN: 1743-422X
DOI: https://doi.org/10.1186/s12985-016-0650-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Generation of mAbs to foot–and–mouth disease virus serotype A and application in a competitive ELISA for serodiagnosis

Abstract

Background

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2016

Analysis of HIV-1 intersubtype recombination breakpoints suggests region with high pairing probability may be a more fundamental factor than sequence similarity affecting HIV-1 recombination

Serological evidence of rift valley fever virus among acute febrile patients in Southern Mozambique during and after the 2013 heavy rainfall and flooding: implication for the management of febrile illness

Equine rhinitis B viruses in horse fecal samples from the Middle East

Characterization of differential antibody production against hepatitis C virus in different HCV infection status

Dengue research: a bibliometric analysis of worldwide and Arab publications during 1872–2015

Responses of primary human nasal epithelial cells to EDIII-DENV stimulation: the first step to intranasal dengue vaccination

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page